Introduction
Apoptosis is the prevalent form of programmed cell death that, when altered, contributes to a number of human diseases (Thompson, 1995) . The inhibition of apoptosis is implicated in diseases such as cancer, autoimmune disorders and viral infections whereas excess apoptosis is linked to other pathological processes such as neurodegenerative disorders, AIDS and stroke. Bcl-2 and related proteins are a growing family of molecules that regulate apoptosis (Adams and Cory, 1998; Chao and Korsmeyer, 1998) . This family includes both death antagonists such as Bcl-2, Bcl-x L , Mcl-1, Bcl-w and A-1 which suppress cell death, and death agonists such as Bax, Bak, Bik, Bad and Bid which promote cell death. They share at least one of four homologous regions termed Bcl homology (BH) domains (BH1 ± BH4), which mediate homo-and heterotypic dimer formation among Bcl-2 family members. Although it is not fully understood how Bcl-2 family proteins regulate the apoptotic pathway, it has been suggested that these protein ± protein interactions involving Bcl-2 family proteins are critical for their biological functions.
Bcl-2 plays an important role in cancer and resistance of cancer to conventional therapies. Bcl-2 can contribute to neoplastic cell expansion by preventing normal cell turnover caused by physiological cell death mechanisms (Reed, 1994; Reed et al., 1996) . High expression of Bcl-2 is found in a wide variety of human cancers and mediates the resistance of cancers to a wide spectrum of chemotherapeutic drugs and g-irradiation which act by inducing apoptosis in tumor cells. By blocking the cell death signals triggered by these drugs, Bcl-2 can interfere with the therapeutic eect of many currently available anticancer drugs (Figure 1) . Therefore, the functional blockade of Bcl-2 or Bcl-x L should either restore the apoptotic process in tumor cells or sensitize these tumors for chemo-and radiotherapies. This notion is supported by data from the clinical trial that antisense oligonucleotides targeted against Bcl-2 gene can inhibit non-Hodgkin's lymphoma in humans (Webb et al., 1997) . Antisense oligonucleotides (Jansen et al., 1998) and single-chain antibodies (Piche et al., 1998) targeting Bcl-2 family proteins have been shown to be eective for improving tumor cell chemosensitivity. An alternative strategy is to use small molecules discovered by either random screening or rational design techniques, which may be more suitable for developing enzymatically stable, cell permeable and orally available agents.
Structural basis for designing ligands for a surface pocket of Bcl-2 or Bcl-x L The three-dimensional structure of human Bcl-x L , a close homolog of Bcl-2 as determined by X-ray crystallography and NMR spectroscopy provided a structural basis for the design and discovery of Bcl-2 binding small molecules (Muchmore et al., 1996) . The crystal structure of rat Bcl-x L was also reported which showed a similar folding as the human protein (Aritomi et al., 1997) . These structures and that of Bcl-2 constructed based on the Bcl-x L structure reveal a hydrophobic surface pocket formed by the conserved BH1, BH2 and BH3 domains. This pocket is essential for the anti-apoptotic function of Bcl-2 or Bcl-x L as studies have shown that mutations at this site abolished their biological function (Yin et al., 1994) . Death agonists, such as Bax, Bak and Bad, use their BH3 domains to bind the surface pocket of Bcl-2 or Bcl-x L and promote apoptosis (Boyd et al., 1995; Chittenden et al., 1995; Zha et al., 1996) . The details of molecular recognition of these BH3 domains with Bcl-2 or Bcl-x L were elucidated by the structure of the complex between Bcl-x L and the BH3 domain of Bak (Sattler et al., 1997) . More recently, the solution structure of Bid, a member of a subset of death agonists that share only the BH3 domain was determined by NMR spectroscopy (Chou et al., 1999; McDonnell et al., 1999) . This provided further insights Oncogene (2000) 19, 6627 ± 6631 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: Z Huang into the mechanism of protein ± protein interactions involving dierent members of the Bcl-2 family.
BH3 peptides that bind Bcl-2 pocket and inhibit protein ± protein interactions
Since the BH3 domains of pro-apoptotic Bcl-2 family members are known to bind the functional surface pocket of anti-apoptotic Bcl-2 or Bcl-x L and promote programmed cell death, they provide natural templates for designing synthetic Bcl-2 binding peptides. Sattler et al. (1997) synthesized peptides containing the BH3 domains of several Bcl-2 family members including Bcl-2, Bcl-x L , Bax, Bik and Bak (Table 1) . These synthetic BH3 peptides displayed widely dierent binding anities to Bcl-x L , with the peptide derived from Bak BH3 (residues 72 ± 87) showing relatively high binding anity (K D =0.34 mM). Another peptide derived from mouse Bad BH3 (residues 140 ± 165 of mBad, see Table  1 ) showed even higher anity for Bcl-x L with the K D value of 6 nM (Kelekar et al., 1997) . Using an in vitro protein ± protein binding assay, Ottilie et al. (1997) and Diaz et al. (1997) evaluated the eects of peptides (either 16 amino acids or longer) derived from the BH3 domains of Bak, Bax and Bad in blocking the heterodimer formation of Bcl-x L with death agonists. These BH3 peptides were shown to inhibit Bcl-x L -Bax and Bcl-x L -Bad interactions in a dose-dependent manner. Peptides derived from Bad BH3 which had higher anity for Bcl-x L were more potent than other BH3-derived peptides in blocking protein ± protein interactions involving Bcl-x L .
Apoptosis triggered by BH3 peptides in cell-free systems
Using a cell-free system based on extracts of Xenopus eggs as a biochemical model for the apoptotic process, the biological activity of synthetic BH3 peptides in triggering apoptosis was examined (Cosulich et al., 1997) . Peptides of 16 amino acids derived from the BH3 domains of Bak, Bax or Bid were found to have apoptosis inducing activity by causing rapid activation of caspases, whereas a Bak BH3 mutant peptide containing Ala substitution at Leu-78, which is critical for Bcl-x L binding (Sattler et al., 1997) and a peptide derived from the BH3 domain of anti-apoptotic Bcl-2 did not show any eect. Since cytochrome c release plays an important role in apoptosis, the activity of synthetic BH3 peptides in aecting cytochrome c release in isolated rat mitochondria was evaluated. Whereas one study indicated the lack of activity of a 16-amino acid peptide derived from Bax BH3 domain in inducing cytochrome c release (Jurgensmeier et al., 1998) , another study observed signi®cant cytochrome c release after treatment with a 20-amino acid Bax BH3 peptide (residues 55 ± 74) or a 15-amino acid Bak BH3 peptide (residues 73 ± 87) (Narita et al., 1998) . In a recent conference report (Morgan et al., 2000) , synthetic peptides derived from the BH3 domain of Bak or Bax, when introduced into prostate carcinoma PC-3 and DU145 cells by electroporation, were shown to cause apoptosis in these cells which could be blocked by a broad spectrum caspase inhibitor ZVAD-fmk. In addition, these peptides diminished the association between Bcl-2 and Bak in PC-3 cells.
Cell permeable BH3 peptides that induce apoptosis in intact cells
To develop cell permeable BH3 peptides capable of crossing cell membrane and triggering intracellular apoptotic signals, BH3 peptides were linked with transporter molecules that can deliver functional peptides into the cell. Using the internalization domain of the Antennapedia (Ant) protein as a tranporter, Holinger et al. (1999) found that a fusion Ant-BH3 peptide combining the 16-amino acid Ant internalization sequence (RQIKIWFQNRRMKWKK) and the Bak BH3 sequence (residues 71 ± 89) caused the activation of caspases and triggered apoptosis in intact HeLa cells. While microinjection of recombinant Bcl-x L into these cells suppressed programmed cell death induced by Fas, Ant-BH3 peptide was shown to antagonize the function of Bcl-x L and inhibit its ability to suppress Fas-induced apoptosis. It was suggested that the cell killing eect of Ant-BH3 peptide was due to its binding to Bcl-2 related death antagonists because a mutant Ant-BH3 peptide containing a single Ala substitution at Val-78 lost Bcl-x L binding and was incapable of inducing apoptosis. Interestingly, Ant-BH3 appeared to trigger apoptosis in a cytochrome cindependent manner since the peptide did not cause the early loss of mitochondrial membrane potential or release of cytochrome c from the mitochondria.
Using a dierent transporter based on fatty acids, Wang et al. (2000b) designed another class of cell permeable Bcl-2 binding peptides by chemically attaching the N-terminus of synthetic BH3 peptides Figure 1 The resistance of tumor cells to conventional chemotherapy or radiation therapy mediated by high expression of Bcl-2 The amino acid sequence of the BH3 domain of mouse Bad (mBad) is shown here because it has been used for peptide design. All other BH3 sequences are from human proteins. The numbering of residues corresponds to that in the native protein.
c The BH3 domains of death antagonists Bcl-2 and Bcl-x L are included for comparison with those of death agonists Bcl-2 as a target for anticancer drug design Z Huang with a decanoic acid as the cell permeable moiety (CPM) (Figure 2 Non-peptidic small molecules that inhibit the function of Bcl-2 or Bcl-x L Two natural products have been suggested to antagonize the anti-apoptotic function of Bcl-2 or Bcl-x L . Nakashima et al. (2000) reported that a natural product Tetrocarcin A inhibited mitochondrial functions of Bcl-2 and suppressed its anti-apoptotic activity ( Figure 3a ). Tetrocarcins were originally discovered from random screening to have antibacterial activity against Gram-positive bacteria and antitumor activity against experimental murine tumors (Tomita et al., 1980) . In the recent study by Nakashima et al. (2000) , the screening of a library of natural products using cells overexpressing Bcl-2 or Bcl-x L led to the identi®cation of Tetrocarcin A. It was found that Tetrocarcin A, when combined with anti-Fas antibody, tumor necrosis factor a, staurosporine, or Bax, induced apoptosis in these cells. In addition, Tetrocarcin A inhibited mitochondrial functions regulated by Bcl-2 and thereby resulted in Fas-induced mitochondrial transmembrane potential loss and cytochrome c release. In another conference report (Tzung et al., 1999) , Antimycin A was shown to mimic the activity of synthetic BH3 peptides and selectively induce apoptosis in cell lines overexpressing Bcl-x L (Figure 3b ). Antimycin A was originally discovered as an antibiotic active against a wide variety of fungi, yeasts, insects, and mammals (Tokutake et al., 1994) . Tzung et al. (1999) recently hypothesized that Antimycin A may recognize the surface pocket of Bcl-x L and showed that Antimycin A was able to compete with a BH3 peptide for binding to recombinant Bcl-2 protein. Antimycin A also inhibited the mitochondrial function regulated by Bcl-x L and blocked the channel activity of Bcl-x L . In contrast to the random screening of natural products, another approach to drug discovery is computer-aided design of speci®c ligand molecules based on the high resolution three-dimensional structure of a targeted receptor protein. This approach that exploits both new computational methods and the diversity of existing compound databases for the identi®cation of novel protein binding molecules has become a powerful tool for non-peptidic ligand discovery (Huang, 2000) . Using this computer screening strategy, Wang et al. (2000a) recently reported a low molecular weight organic compound, HA14-1 (Figures 3c and 4) . In vitro binding studies demonstrated the interaction of HA14-1 with the surface pocket of Bcl-2. HA14-1 eectively induced apoptosis in HL-60 cells overexpressing Bcl-2 protein that was associated with the decrease in mitochondrial membrane potential and activation of caspase 9 followed by caspase 3. HA14-1 and related derivatives were synthesized using an ecient method (Yu et al., 2000) .
Conclusions
Bcl-2 family proteins are key regulators of apoptosis and attractive targets to develop a new generation of therapeutics for the treatment of cancer. Structure- (Tzung et al., 1999) and (c) HA14-1 (Wang et al., 2000a) Oncogene Bcl-2 as a target for anticancer drug design Z Huang function studies of these proteins have revealed a surface pocket on anti-apoptotic Bcl-2 and Bcl-x L that is critical for their interactions with other proapoptotic proteins and abilities in suppressing cell death signals. Intensive eorts have been made by a number of laboratories in both academia and pharmaceutical industry to search for small molecules that recognize this surface pocket of Bcl-2 or Bcl-x L and antagonize their biological functions. Several classes of small molecule inhibitors of Bcl-2 function have been reported: (i) synthetic BH3 peptides and their modi®ed analogs with cell membrane crossing properties, (ii) natural products identi®ed from random screening processes, and (iii) organic compounds designed by structure-based and computer-aided techniques.
These various classes of Bcl-2 binding small molecules have provided important tools for probing molecular mechanism of Bcl-2 function and promising leads for developing novel pharmaceutical agents. Studies of synthetic BH3 peptides have yielded insights into the structure and function of native BH3 domains. Modi®cations of these peptides to enhance their cell permeability have been shown to be eective for inducing apoptosis in intact tumor cells. Further eorts in reducing their molecular size (currently 16 ± 25 residues for most BH3 peptides without considering the cell permeable domains) and enhancing their biological half-life (peptides are normally susceptible to enzymatic degradation) may likely lead to peptidomimetic analogs that are more suitable for clinical applications.
As to the natural products that have been found to be active in blocking Bcl-2 function, their mechanism of action and speci®city for the Bcl-2 family needs to be further de®ned. Since these compounds were originally discovered from other functional screening and have other known protein binding targets, it is possible that they possess other biological activities unrelated to Bcl-2. For example, Antimycin A was previously known to bind cytochrome b and the structure-activity relationship of its inhibitory action was characterized (Tokutake et al., 1994) . It remains to be demonstrated how Antimycin A can be transformed into analogs with only Bcl-2 binding speci®city. Since no study regarding the binding of Tetrocarcin A to Bcl-2 or Bcl-x L has been reported, it is not clear whether Tetrocarcin A recognizes the surface pocket of Bcl-2 or Bcl-x L or may actually target other proteins associated with the Bcl-2-regulated apoptotic pathway. Nevertheless, these natural products may provide starting templates for further studies to develop more speci®c inhibitors targeting Bcl-2 family proteins or Bcl-2-regulated cell death process.
Finally, organic compounds discovered by using structure-based techniques represent another source of non-peptidic leads whose potency and speci®city can be optimized. For these de-novo compounds such as HA14-1, recent data suggest that they bind to the Bcl-2 pocket in vitro and induce apoptosis in cells. However, it is still not known whether they may also target other proteins and possess activities unrelated to Bcl-2. Therefore, it must be emphasized that more studies are necessary to further characterize their mechanism of action and assess any potential side eects. The structure of HA14-1 is relatively simple and amenable to modi®cations using medicinal chemistry or combinatorial synthesis techniques. It can be anticipated that studies of small molecule modulators of the biological function of Bcl-2 family proteins will continue to be active areas of basic and clinical research.
